The HOOK3 Knockout NCI-H1975 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population for loss-of-function studies of the human HOOK3 gene. This population derived from NCI-H1975 lung adenocarcinoma cells features HOOK3 gene disruption via CRISPR/Cas9-mediated editing. The polyclonal format provides a heterogeneous knockout pool, enabling robust functional analyses. This model is a valuable tool for dissecting HOOK3-dependent processes in a cancer-relevant context.
The host cell line, NCI-H1975, is a human non-small cell lung cancer (NSCLC) model from a lung adenocarcinoma patient. It harbors activating EGFR L858R and resistance mutation T790M, conferring insensitivity to first-generation EGFR tyrosine kinase inhibitors (TKIs). With epithelial morphology, NCI-H1975 is widely used to study EGFR-TKI resistance, autophagy, and metastasis. Combining this oncogenic background with HOOK3 knockout offers a platform to explore endocytic trafficking and drug sensitivity.
HOOK3 is an adaptor linking cargo vesicles to the dynein-dynactin microtubule motor via the FTS-FHIP scaffold. It interacts with FTS (AKTIP), FHIP1A, FHIP2, and dynein/dynactin subunits to tether Rab7+ late endosomes and LC3+ autophagosomes, driving retrograde transport. Regulated by EGF, mTORC1, and stress, HOOK3 mediates perinuclear lysosome clustering essential for autophagosome-lysosome fusion and autophagy flux. Downstream effects include lysosomal positioning, autophagy clearance, and cell migration. Loss of HOOK3 disrupts endosomal trafficking and autophagic degradation.
In EGFR-mutant NCI-H1975, altered endocytosis and elevated autophagy sustain tumor growth and TKI resistance. HOOK3-dependent lysosome distribution and autophagy are critical as autophagy acts as a pro-survival stress response. HOOK3 knockout may impair autophagic flux, potentially sensitizing cells to EGFR-TKIs. Its role in cell migration also suggests attenuation of metastatic potential. Thus, this model allows investigation of synthetic lethal interactions and resistance mechanisms in a clinically relevant genetic context.
Research applications include studying HOOK3 in autophagy, endosomal trafficking, and migration in EGFR-mutant NSCLC. The model supports synthetic lethal screens, drug sensitivity assays, and migration/invasion studies. Suitable assays: western blotting for LC3 and p62, immunofluorescence for LAMP1/LC3 colocalization, Transwell migration, co-immunoprecipitation of HOOK3-dynein complexes, and RNA-seq. Drug sensitivity testing with EGFR-TKIs assesses treatment response. For further information, please contact Ascent Research.
